Sichuan Biokin Pharmaceutical (SHA:688506) plans to acquire 7.91% of Connexus Therapeutics for $5 million, according to a Shanghai bourse on Friday.
The pharmaceutical company will subscribe for Connexus Therapeutics' 3.9 million Series A preferred shares through its subsidiary, Panku Capital.
Connexus is a pharmaceutical company focused on the development of small-molecule drugs in the oncology field.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.